bioAffinity Technologies (BIAFW) — customer relationships briefing for investors

bioAffinity Technologies commercializes CyPath® Lung, a non‑invasive diagnostic test developed and distributed through its subsidiary Precision Pathology Laboratory Services (PPLS). The company monetizes through fee‑for‑service diagnostic revenue (patient service, histology and medical director fees), direct sales to institutional buyers, and third‑party reimbursement pathways; recent commercial activity includes federal procurement channels that extend access to veterans and active military personnel. Investors should treat the DoD relationship as a credibility and distribution milestone rather than a large, recurring revenue stream today. For a closer read on counterparty exposure and procurement signals, visit https://nullexposure.com/.

Why the Department of Defense relationship matters to the story

According to bioAffinity’s Form 10‑K for the year ended December 31, 2024, the U.S. Department of Defense purchased CyPath Lung tests for an observational study titled “Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath® Lung Assay.” The work included R&D use of bronchoalveolar lavage fluid to assess cardiopulmonary function post‑COVID‑19, with activity described as beginning in Q4 2023 and continuing through 2024. (Source: company Form 10‑K, year ended Dec. 31, 2024.)

This relationship performs three practical functions for bioAffinity: (1) validation and clinical credibility through a government observational study; (2) initial institutional revenue and procurement track record that supports federal contracting; and (3) pathway access to military and VA health systems once tests are listed on federal schedules. The commercial economic impact to date is modest but directional: CyPath Lung testing revenue rose roughly 1,400% to $0.5 million for the year ended December 31, 2024 (from $35,000 in the prior year), driven by more than 600 tests delivered. (Source: company 2024 disclosures.)

How the procurement signals translate to commercial posture

bioAffinity’s public filings show a deliberate shift from purely clinic/patient sales toward institutional buyers and government payors. In October 2024 CyPath Lung was awarded listing on the U.S. Federal Supply Schedule (FSS), which makes the test accessible across federal health systems and simplifies procurement by VA and military facilities. That listing is a structural signal: FSS placement reduces friction for government buyers and raises the probability of repeat institutional orders, even if individual contract values remain modest.

At the same time, the company still derives the majority of recurring revenue from patient service fees sold to physicians and billed to insurance or patients, which creates a dual commercial model: retail medical services plus targeted institutional sales. The firm notes limited prior experience in sales and distribution, so the current posture is that of an early commercial-stage diagnostics company leveraging a mix of payor channels and one-off government engagements to scale.

Customer mix, concentration and commercial risk

bioAffinity’s publicly disclosed relationships indicate a mixed counterparty base: government buyers, individual patients (through physicians), and third‑party payors such as Medicare and private insurers. These characterizations come from company filings describing billing arrangements and payor diversity. The implications for investors are clear:

• Concentration: The DoD engagement is important symbolically but not large enough yet to shift the revenue mix; CyPath Lung revenue remains in the low‑millions range for FY2024. (Source: Form 10‑K disclosures on revenue.)
• Criticality: Government endorsement and FSS listing increase the test’s institutional criticality, particularly for veteran and military screening programs, but the company’s overall volume and revenue base remain early and therefore sensitive to single‑contract variability.
• Contracting posture: The business contracts with patients, physicians, insurers, and government payors—each with different billing rules and timelines—so operating cash flow and reimbursement timing carry elevated execution risk.
• Maturity: The commercial program is early stage: revenue growth is meaningful in percentage terms but absolute dollars are small relative to operating losses reported for the period. (Source: company financial metrics for FY2024 and latest quarter.)

For investors monitoring procurement and counterparty risk, Null Exposure’s counterparty lens is useful to track shifts in buyer composition and the cadence of government orders—review further at https://nullexposure.com/.

Operational constraints and what they signal about execution

Company‑level signals extracted from disclosures present an operational profile that investors must internalize when modeling growth:

• Government counterparty presence: Filings cite government payors and direct government purchases, with explicit DoD activity documented for Q4 2023–2024. This shifts the sales playbook toward federal procurement cycles and compliance obligations. (Source: company 10‑K.)
• Individual patient revenue remains core: The firm explicitly states that the majority of revenue stems from patient service fees, which keeps reimbursement complexity and payer mix central to revenue forecasting. (Source: company disclosures.)
• Service orientation: Revenue streams are categorized as patient service fees, histology fees, and medical director fees, confirming that the company operates primarily as a clinical services provider rather than a high‑margin product licensor. (Source: company 10‑K.)
• Spend band and scale: CyPath Lung testing revenue increased to approximately $0.5 million in FY2024, consistent with a spend band indicative of early commercial traction rather than enterprise‑scale contracts. (Source: company financial disclosures.)

These constraints imply a company that is commercializing successfully at small scale but still must execute on reimbursement, distribution, and sales channel build‑out to convert DoD and FSS access into recurring, material revenues.

Relationship-by-relationship breakdown

U.S. Department of Defense
The Department of Defense purchased CyPath Lung tests for an observational study on detecting abnormal respiratory cell populations and used bronchoalveolar lavage fluid for related cardiopulmonary R&D; purchases occurred beginning in Q4 2023 and continued through 2024. (Source: Form 10‑K for the year ended Dec. 31, 2024; company disclosures.)

Investment implications and near‑term monitoring checklist

bioAffinity’s commercial narrative is now a balance of clinical validation and small‑scale commercialization. The DoD engagement and FSS listing are positive strategic signals that de‑risk federal adoption, but the company remains dependent on successful scaling of PPLS sales and complex payer reimbursement. Key items for investors to monitor in the next 12–18 months:

• Quarterly revenue cadence and the trajectory of CyPath Lung test volumes relative to the FY2024 base of ~600 tests. (Source: company revenue disclosures.)
• Evidence of repeat or expanded orders from military/VA facilities under FSS procurement. (Source: FSS listing noted in company disclosures.)
• Changes in payer mix or reimbursement policies that affect per‑test net revenue and collection timing. (Source: 10‑K billing language.)
• Progress in building out sales, marketing and distribution capacity, and any material commercial partnerships or lab network expansion.

For regular updates on counterparty relationships, procurement wins, and how they translate into revenue, visit https://nullexposure.com/.

Final thought: bioAffinity has converted clinical innovation into initial commercial traction and federal procurement access; the path to material revenue requires converting that access into predictable, repeatable institutional demand while stabilizing reimbursement and scaling patient volumes. For ongoing counterparty and procurement analysis, see https://nullexposure.com/.